Physician profile
David M Kahn
NPI 1811941826
$47,422.17
in general payments reported to CMS, 2019-2025
74 companies · $6,327 in 2025
The $6,327 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,435 · 2020: $7,975 · 2021: $6,820 · 2022: $5,964 · 2023: $6,559 · 2024: $5,342 · 2025: $6,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,729 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,789.56 |
| Consulting Fee | $1,729.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $708.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,686.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,682.40 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Jazz Pharmaceuticals INC. | $4,106.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,204.21 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Pharmacosmos Therapeutics INC. | $2,986.32 | 2021-2025 | Monoferric |
| Glaxosmithkline, LLC. | $2,605.88 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $2,587.74 | 2019-2025 | |
| Celgene Corporation | $1,423.85 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Merck Sharp & Dohme LLC | $1,398.64 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $1,246.22 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $1,218.74 | 2019-2025 | Talvey, Darzalex, Erleada |
| Genzyme Corporation | $1,140.13 | 2019-2025 | |
| Eisai INC. | $1,096.07 | 2019-2025 | |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Seagen INC. | $975.87 | 2019-2025 | Tukysa, Tivdak, Padcev |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $906.42 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $862.63 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Astellas Pharma US INC | $859.69 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Genentech USA, INC. | $798.76 | 2019-2024 | Venclexta, Polivy, Lunsumio |
| Daiichi Sankyo INC. | $695.57 | 2019-2025 | Enhertu, Datroway |
| Exelixis INC. | $685.69 | 2019-2025 | Cabometyx |
| Sirtex Medical INC | $664.63 | 2022-2023 | Sir-Spheres Microspheres |
| Amgen INC. | $622.86 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $591.89 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $556.39 | 2019-2025 | |
| Array Biopharma INC | $431.56 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $316.48 | 2020-2024 | |
| Adaptive Biotechnologies Corporation | $309.41 | 2022-2025 | Clonoseq |
| Foundation Medicine, INC. | $293.11 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $270.33 | 2020-2024 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $266.24 | 2022-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $263.71 | 2022-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $246.37 | 2019-2024 | Onivyde, Somatuline Depot |
| Sobi, INC | $229.77 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $209.64 | 2019-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.42 | 2019-2025 | |
| Pharmaessentia USA Corporation | $177.27 | 2022-2025 | Besremi |
| Zap Surgical Systems, INC. | $172.70 | 2020 | |
| Dendreon Pharmaceuticals LLC | $149.06 | 2020-2025 | Provenge |
| Servier Pharmaceuticals LLC | $144.82 | 2024-2025 | |
| Immunogen, INC. | $135.31 | 2023 | Elahere |
| Taiho Oncology, INC. | $128.81 | 2023-2025 | |
| Beigene USA, INC. | $127.85 | 2022-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $122.71 | 2022-2025 | |
| Dova Pharmaceuticals | $115.69 | 2021 | |
| Mirati Therapeutics, INC. | $114.60 | 2023-2024 | Krazati |
| Abbvie INC. | $114.16 | 2023-2025 | |
| Global Blood Therapeutics, INC. | $104.44 | 2020-2022 | |
| Gilead Sciences, INC. | $101.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Tersera Therapeutics LLC | $91.20 | 2024-2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $90.47 | 2021-2025 | Qinlock, Tgct |
| Fosun Pharma USA INC. | $84.80 | 2023 | |
| Amneal Pharmaceuticals LLC | $69.64 | 2023-2024 | Neupogen, Avastin, Neulasta |
| Janssen Pharmaceuticals, INC | $65.70 | 2019-2020 | |
| Beone Medicines USA, INC. | $61.40 | 2025 | Tevimbra |
| Caris Mpi, INC. | $52.98 | 2025 | Mi Cancer Seek |
| Tg Therapeutics, INC. | $47.54 | 2022 | |
| Mylan Institutional INC. | $42.46 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $39.34 | 2019 | |
| Verastem, INC. | $37.79 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $36.98 | 2022-2025 | Pyrukynd |
| Myovant Sciences INC. | $35.76 | 2021 | |
| Aurobindo Pharma USA, INC. | $30.71 | 2019 | |
| Stemline Therapeutics INC. | $29.61 | 2025 | Orserdu |
| Tempus Ai, INC | $26.28 | 2024 | Xt Cdx |
| Radius Health, INC. | $23.44 | 2025 | Tymlos |
| Emmaus Medical, INC. | $23.26 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $17.23 | 2019 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Advanced Accelerator Applications | $15.23 | 2019 | |
| Heron Therapeutics, INC. | $15.20 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.98 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.